KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 90 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 1.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $356,432 | 0.0% | 91,628 | 0.0% | 0.00% | – |
| Q1 2023 | $356,432 | +26.5% | 91,628 | +10.6% | 0.00% | – |
| Q4 2022 | $281,775 | -99.9% | 82,875 | +15.1% | 0.00% | – |
| Q3 2022 | $393,238,000 | +22.3% | 72,022 | +1.1% | 0.00% | – |
| Q2 2022 | $321,433,000 | -29.8% | 71,271 | +14.7% | 0.00% | – |
| Q1 2022 | $457,824,000 | -22.4% | 62,120 | -32.3% | 0.00% | – |
| Q4 2021 | $589,766,000 | +20.1% | 91,721 | +8.7% | 0.00% | – |
| Q3 2021 | $491,167,000 | -43.6% | 84,393 | 0.0% | 0.00% | – |
| Q2 2021 | $870,936,000 | +48.8% | 84,393 | +51.7% | 0.00% | – |
| Q1 2021 | $585,174,000 | -39.9% | 55,625 | -11.5% | 0.00% | – |
| Q4 2020 | $973,383,000 | +32.6% | 62,880 | +25.1% | 0.00% | – |
| Q3 2020 | $733,825,000 | -25.4% | 50,262 | -3.3% | 0.00% | -100.0% |
| Q2 2020 | $984,179,000 | -1.5% | 51,963 | -0.1% | 0.00% | 0.0% |
| Q1 2020 | $999,228,000 | -20.0% | 52,016 | -20.2% | 0.00% | 0.0% |
| Q4 2019 | $1,249,424,000 | +139.9% | 65,176 | +20.4% | 0.00% | – |
| Q3 2019 | $520,749,000 | +222.3% | 54,132 | +100.7% | 0.00% | – |
| Q2 2019 | $161,586,000 | +106.4% | 26,976 | +101.2% | 0.00% | – |
| Q1 2019 | $78,285,000 | -37.7% | 13,405 | 0.0% | 0.00% | – |
| Q4 2018 | $125,605,000 | +123042.2% | 13,405 | +27.7% | 0.00% | – |
| Q3 2016 | $102,000 | +45.7% | 10,500 | 0.0% | 0.00% | – |
| Q2 2016 | $70,000 | -25.5% | 10,500 | 0.0% | 0.00% | – |
| Q1 2016 | $94,000 | -32.4% | 10,500 | 0.0% | 0.00% | – |
| Q4 2015 | $139,000 | +25.2% | 10,500 | 0.0% | 0.00% | – |
| Q3 2015 | $111,000 | -61.2% | 10,500 | 0.0% | 0.00% | – |
| Q2 2015 | $286,000 | -91.6% | 10,500 | -90.6% | 0.00% | -100.0% |
| Q1 2015 | $3,416,000 | -18.7% | 111,600 | -0.6% | 0.00% | -25.0% |
| Q4 2014 | $4,203,000 | +1385.2% | 112,300 | +1286.4% | 0.00% | – |
| Q3 2014 | $283,000 | -80.3% | 8,100 | -82.6% | 0.00% | -100.0% |
| Q1 2014 | $1,439,000 | +34.1% | 46,600 | -0.4% | 0.00% | +100.0% |
| Q4 2013 | $1,073,000 | – | 46,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
| Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
| Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
| Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
| Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
| Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
| Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
| Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
| Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |